SCHEMBL4289196

SCHEMBL4289196

CNC(=O)c1cc(Oc2cccc(CCNC(=O)c3ccc(OC)cc3)c2)ccn1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 1/20 0.55
CA1 P00915 2/20 0.54
CA2 P00918 2/20 0.54
CA7 P43166 2/20 0.54
CA9 Q16790 2/20 0.54
CA14 Q9ULX7 2/20 0.54
CSF1R P07333 1/20 0.53
BRAF P15056 5/20 0.50
KDR P35968 3/20 0.50
KMT2A Q03164 3/20 0.50
RAF1 P04049 1/20 0.50
MMP13 P45452 1/20 0.49
ROCK2 O75116 2/20 0.48
ROCK1 Q13464 2/20 0.48
CYP3A4 P08684 1/20 0.48
CYP2D6 P10635 1/20 0.48
CYP2C9 P11712 1/20 0.48
PRKACA P17612 1/20 0.48
GSK3A P49840 1/20 0.48
GSK3B P49841 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3986441 0.92 RAB9A (0.55) RAB9ACA1CA2CA7CA9
SCHEMBL3991948 0.92 KDM5B (0.51) RAB9ACA1CA2CA7CA9
SCHEMBL5124752 0.91 KDR (0.51) RAB9ACA1CA2CA7CA9
SCHEMBL14266582 0.91 RAB9A (0.51) RAB9ACA1CA2CA7CA9
SCHEMBL5131048 0.90 RAB9A (0.57) RAB9ACA1CA2CA7CA9
SCHEMBL3992181 0.90 BRAF (0.54) RAB9ACA1CA2CA7CA9
SCHEMBL14266595 0.90 RAB9A (0.58) RAB9ACSF1RBRAFKDRKMT2A
SCHEMBL14273316 0.89 CA1 (0.50) RAB9ACA1CA2CA7CA9
SCHEMBL14266549 0.89 TRPV1 (0.59) BRAFKDRRAF1ROCK2ROCK1
SCHEMBL14266543 0.89 PPARG (0.50) RAB9ACA1CA2CA7CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2061761-A1 PHENETHYLAMIDE DERIVATIVES WITH KINASE INHIBITORY ACTIVITY Millennium Pharmaceuticals, Inc. (US) 2009-05-27 EP disclosed
US-20080064729-A1 Phenethylamide derivatives with kinase inhibitory activity MILLENNIUM PHARMACEUTICALS, INC. (US) 2008-03-13 US disclosed
US-20080064729-A1 Phenethylamide derivatives with kinase inhibitory activity MILLENNIUM PHARMACEUTICALS, INC. (US) 2008-03-13 US disclosed
WO-2008030448-A1 PHENETHYLAMIDE DERIVATIVES WITH KINASE INHIBITORY ACTIVITY MILLENNIUM PHARMACEUTICALS, INC. (US) 2008-03-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080064729-A1 Phenethylamide derivatives with kinase inhibitory activity MAP4K5, MAP3K5, MAP4K2 RAB9A 1730/4885CA1 4235/4885CA2 1144/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.